FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Monthly Prescribing Reference15h
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
Interesting Engineering on MSN10h
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
ENDPOINTS NEWS18h
Septer­na ends Phase 1 tri­al for hy­poparathy­roidism drug; Sanofi’s Mer­ilog is ap­proved
Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Sanofi: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed ...